Date/heure
Date(s) - 11 Fév. 2025 - 12 Fév. 2025
0h00
Virtual Event – February 11 & 12, 2025
The Mitogen Activated Protein Kinase (MAPK) pathway is one of the most commonly mutated signalling pathways in human cancers. While a range of small molecule inhibitors have been developed to inhibit the upstream and downstream effectors of this pathway, resistance remains a significant challenge.
Target audience
Those in academia and industry that are interested in the role of the MAPK pathway in the context of genetically targeted and immune-based anticancer therapies. The meeting will focus on both the mechanistic aspects of gene regulation, target validation, and drug development, as well as emerging clinical and translational opportunities.
Topics to be covered:
- Regulation of MAPK signalling
- Drug resistance mechanisms
- Rational combination therapies
- Cross-resistance to immune modulators
Deadline for abstract submission: December 16, 2024
Deadline for registration: January 24, 2025
Catégories